MAISA

@MaisaCorp

MAISA's Platform is based MAISA's proprietary Optimization on Mathematical Probability Algorithm (OMPA) which derived majority from applied mathematics.

U.S.A
Vrijeme pridruživanja: travanj 2013.

Tweetovi

Blokirali ste korisnika/cu @MaisaCorp

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @MaisaCorp

  1. Prikvačeni tweet
    23. velj 2015.

    “I’m not greedy. I just want my 1% of 's money." by

    Poništi
  2. prije 3 sata

    obtained an exclusive world-wide license to develop and commercialize the investigational humanized onoclonal antibody XmAb7195 from Xencor . will make an upfront payment to of $5 million in cash and $5 million in equity

    Poništi
  3. prije 3 sata

    its annamycin drug has received a fast track designation from the US Food and Drug Administration. Moleculin Biotech is WPD's development partner for annamycin.

    Poništi
  4. prije 3 sata

    intends to discuss a plan with the US and European regulators to conduct a trial that would serve as the basis for accelerated approval of its treatment for relapsed or refractory acute myeloid leukemia

    Poništi
  5. prije 3 sata

    the US patent office Wednesday said it's unlikely the company will win cases challenging the government ownership of the patents underlying HIV drugs.

    Poništi
  6. prije 3 sata

    Nestle Health Science was making an additional $200 million equity investment in the biopharmaceuticals company, boosting its total investment to $473 million.

    Poništi
  7. prije 3 sata

    FDA approved the company's supplemental new drug application for a delayed-release formulation of its pancreaze prescription medicine used to treat people who cannot digest food normally due to pancreas disorders

    Poništi
  8. prije 3 sata

    Preliminary Data from NIH/NIAID-sponsored Phase 2 Clinical Trial of BiondVax’s M-001 Universal Influenza Vaccine both primary objectives were achieved. Analysis of the data is ongoing, and the clinical study report (CSR) is expected in Q2 2020.

    Poništi
  9. prije 3 sata

    R/S 1:10

    Poništi
  10. prije 3 sata

    Files For Offering Of 6 Million Shares Of Common Stock

    Poništi
  11. prije 3 sata

    Drugmakers racing to find a vaccine or effective treatment for the deadly new coronavirus in China cautioned that they have a long way to go.

    Poništi
  12. 5. velj

    Achieves 50% Patient Enrollment in Phase 3 Mino-Lok® Pivotal Trial The next major milestone in the Mino-Lok trial, expected to be achieved in the first half of 2020, will be the 75% interim analysis for superior efficacy.

    Poništi
  13. 4. velj

    BofA Securities Initiates Coverage on Incyte With Neutral Rating, $82 Price Target

    Poništi
  14. 4. velj

    Gilead Sciences Sets Quarterly Dividend Of $0.68 Per Share

    Poništi
  15. 4. velj

    has signed an exclusive license agreement with Equinox Science LLC to develop vorolanib, a tyrosine kinase inhibitor, for the treatment of wet age-related macular degeneration, diabetic retinopathy and retinal vein occlusion.

    Poništi
  16. 4. velj

    has been approved by the New Jersey Economic Development Authority to transfer approximately $5.5 million of the total $6.0 million of its available tax benefits

    Poništi
  17. 4. velj

    Appoints David Ailinger as Vice President, Business Development

    Poništi
  18. 4. velj

    Reaffirms Projection For Second Pre-Planned Interim Efficacy Analysis For Phase III Optima Study

    Poništi
  19. 4. velj

    licensed U.S. rights from Bioeq AG to Bioeq’s Lucentis® (ranibizumab) biosimilar candidate. Bioeq filed a Biologic Licensing Application with the U.S. Food and Drug Administration in December 2019.

    Poništi
  20. 4. velj

    announced a one-for-ten reverse stock split

    Poništi
  21. 4. velj

    submitted a biologics license application to the US Food and Drug Administration for Ryoncil to treat children with steroid-refractory acute graft versus host disease, a syndrome characterized by organ inflammation associated with bone marrow transplants.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·